Nanovibronix (NASDAQ:FEED) Stock Rating Upgraded by Wall Street Zen

Nanovibronix (NASDAQ:FEED) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nanovibronix in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Nanovibronix presently has an average rating of “Sell”.

Nanovibronix Stock Down 1.6%

Nanovibronix stock traded down $0.01 during mid-day trading on Friday, hitting $0.53. 523,274 shares of the stock were exchanged, compared to its average volume of 362,778. The firm has a market capitalization of $3.22 million, a PE ratio of -0.06 and a beta of 1.56. Nanovibronix has a 12 month low of $0.42 and a 12 month high of $17.40. The firm’s fifty day moving average price is $0.84.

Nanovibronix (NASDAQ:FEED) last posted its quarterly earnings data on Monday, May 18th. The company reported ($6.88) EPS for the quarter. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%. The firm had revenue of $0.65 million during the quarter.

Insider Buying and Selling at Nanovibronix

In related news, insider Christian Michael Glibert sold 210,000 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $0.69, for a total transaction of $144,900.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.40% of the stock is owned by corporate insiders.

About Nanovibronix

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.